A study is a question, not a treatment promise.

The registry record is the source of status—not the study advertisement.

1. ClinicalTrials.gov, API v2 and each linked NCT study record. 40 open, coming or invitation-only records, 18 active records closed to enrollment, and 1 suspended record were queried and human-checked August 28, 2026.
2. ClinicalTrials.gov, protocol registration definitions: recruiting, not yet recruiting, enrolling by invitation, and active not recruiting.
3. ClinicalTrials.gov, How to Read a Study Record: sponsor-entered status, study contacts, locations, eligibility and update dates.
4. U.S. Food and Drug Administration, Psychedelic Drugs: Considerations for Clinical Investigations, final guidance, July 2026.
5. U.S. Food and Drug Administration, Development and Approval Process: research stages and what FDA approval means.
6. U.S. Food and Drug Administration, access to investigational drugs: clinical trials and expanded-access routes are distinct.
7. Drug Enforcement Administration, Hallucinogens Drug Fact Sheet, 2024 edition: federal controlled-substance status and risks.
8. Governor of California, SB 58 veto message, October 7, 2023: the statewide decriminalization proposal did not become law.

Educational information, not medical advice, legal advice, research recruitment, a recommendation to enroll, or a claim that a study will accept you. Registry and posted eligibility ranges checked August 28, 2026. A weekly automated watch checks every curated record and unions two high-recall ClinicalTrials.gov searches; new or changed records open an editorial review item and never publish themselves. Next full human review is due November 26, 2026. Licensed-prescriber and California legal review pending. Paid for by participating therapists. Inclusion is computed, never purchased. No ads. No data sold.